Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL

In recent years, it has become increasingly clear that successful treatment of cancer is possible through the induction of anti-tumor immunity combined with killing of tumor cells. One approach to reach this is to apply cancer vaccines comprising tumor-specific antigens to elicit cellular immunity a...

Full description

Bibliographic Details
Main Authors: Lien Van Hoecke, Xavier Saelens
Format: Article
Language:English
Published: Shared Science Publishers OG 2018-10-01
Series:Cell Stress
Subjects:
Online Access:http://www.cell-stress.com/researcharticles/therapeutic-anti-tumor-immunity-directed-against-neo-epitopes-by-intratumor-delivery-of-mrna-encoding-mlkl/
_version_ 1818007243225825280
author Lien Van Hoecke
Xavier Saelens
author_facet Lien Van Hoecke
Xavier Saelens
author_sort Lien Van Hoecke
collection DOAJ
description In recent years, it has become increasingly clear that successful treatment of cancer is possible through the induction of anti-tumor immunity combined with killing of tumor cells. One approach to reach this is to apply cancer vaccines comprising tumor-specific antigens to elicit cellular immunity and chemotherapy to reduce the tumor mass. However, in some cases the dying tumor cell can itself become the vaccine, in particular when the antineoplastic treatment induces so called immunogenic cell death. Immunogenic cell death is characterized by the exposure of damage associated molecular patterns (DAMPs). DAMPs are recognized by innate immune cells which subsequently can prime effector T cell responses against tumor-specific antigens. Unfortunately, many tumors resist exogenous immunogenic cell death stimuli through acquired mutations in cell death signaling pathways. In our recent study (Nat Commun, 9(1):3417), we aimed to overcome these issues through the direct delivery in tumor cells of hypo-inflammatory messenger RNA (mRNA) that codes for mixed lineage kinase domain-like (MLKL) protein, an executioner of necroptosis. This mRNA-based treatment resulted in the potent induction of systemic cellular anti-tumor immune responses that were associated with the regression of the treated as well as distal non-treated tumor cells, as demonstrated in mouse models of transplantable tumors.
first_indexed 2024-04-14T05:13:18Z
format Article
id doaj.art-0f5b98d688cb4fcda145de7460643320
institution Directory Open Access Journal
issn 2523-0204
language English
last_indexed 2024-04-14T05:13:18Z
publishDate 2018-10-01
publisher Shared Science Publishers OG
record_format Article
series Cell Stress
spelling doaj.art-0f5b98d688cb4fcda145de74606433202022-12-22T02:10:28ZengShared Science Publishers OGCell Stress2523-02042018-10-0121027928110.15698/cst2018.10.160Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKLLien Van Hoecke0Xavier Saelens1VIB-UGent Center for Medical Biotechnology, VIB, 9000 Ghent, Belgium.VIB-UGent Center for Medical Biotechnology, VIB, 9000 Ghent, Belgium.In recent years, it has become increasingly clear that successful treatment of cancer is possible through the induction of anti-tumor immunity combined with killing of tumor cells. One approach to reach this is to apply cancer vaccines comprising tumor-specific antigens to elicit cellular immunity and chemotherapy to reduce the tumor mass. However, in some cases the dying tumor cell can itself become the vaccine, in particular when the antineoplastic treatment induces so called immunogenic cell death. Immunogenic cell death is characterized by the exposure of damage associated molecular patterns (DAMPs). DAMPs are recognized by innate immune cells which subsequently can prime effector T cell responses against tumor-specific antigens. Unfortunately, many tumors resist exogenous immunogenic cell death stimuli through acquired mutations in cell death signaling pathways. In our recent study (Nat Commun, 9(1):3417), we aimed to overcome these issues through the direct delivery in tumor cells of hypo-inflammatory messenger RNA (mRNA) that codes for mixed lineage kinase domain-like (MLKL) protein, an executioner of necroptosis. This mRNA-based treatment resulted in the potent induction of systemic cellular anti-tumor immune responses that were associated with the regression of the treated as well as distal non-treated tumor cells, as demonstrated in mouse models of transplantable tumors.http://www.cell-stress.com/researcharticles/therapeutic-anti-tumor-immunity-directed-against-neo-epitopes-by-intratumor-delivery-of-mrna-encoding-mlkl/immunogenic cell deathmRNA-treatmentimmunotherapy
spellingShingle Lien Van Hoecke
Xavier Saelens
Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
Cell Stress
immunogenic cell death
mRNA-treatment
immunotherapy
title Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
title_full Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
title_fullStr Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
title_full_unstemmed Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
title_short Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
title_sort therapeutic anti tumor immunity directed against neo epitopes by intratumor delivery of mrna encoding mlkl
topic immunogenic cell death
mRNA-treatment
immunotherapy
url http://www.cell-stress.com/researcharticles/therapeutic-anti-tumor-immunity-directed-against-neo-epitopes-by-intratumor-delivery-of-mrna-encoding-mlkl/
work_keys_str_mv AT lienvanhoecke therapeuticantitumorimmunitydirectedagainstneoepitopesbyintratumordeliveryofmrnaencodingmlkl
AT xaviersaelens therapeuticantitumorimmunitydirectedagainstneoepitopesbyintratumordeliveryofmrnaencodingmlkl